Table 3. Comparison of clinicopathological characteristics between lobectomy and wedge resection groups in patients with stage IA2 non-small cell lung cancer.

Variables	Lobectomy group (n=235)	Wedge resection group (n=29)	P value
Age (±SD)	63.6 (±10.5)	69.4 (±8.8)	0.005
Sex, n (%)			0.010
Male	103 (43.8)	20 (69.0)
Female	132 (56.2)	9 (31.0)
Current or former smoker, n (%)	83 (35.3)	16 (55.2)	0.037
Serum CEA level (ng/mL) (±SD)	2.6 (±3.7)	4.3 (±10.1)	0.380
SUVmax (±SD)	3.9 (±3.0)	4.9 (±3.7)	0.228
Involved lobe, n (%)			0.043
Right upper	89 (37.9)	7 (24.1)
Right middle	17 (7.2)	1 (3.4)
Right lower	52 (22.1)	3 (10.3)
Left upper	45 (19.1)	10 (34.5)
Left lower	32 (13.6)	8 (27.6))
Pulmonary function
FEV1 (%) (±SD)	96.3 (±17.6)	88.9 (±16.4)	0.034
DLCO (%) (±SD)	88.6 (±17.2)	74.5 (±16.3)	<0.001
Surgical approach, n (%)			0.589
VATS	197 (83.8)	26 (89.7)
Open thoracotomy	38 (16.2)	3 (10.3)
Postoperative hospital stay (days) (±SD)	6.6 (±4.0)	5.3 (±2.8)	0.099
Postoperative complications, n (%)	34 (14.5)	2 (6.9)	0.391
Operative mortality, n (%)	1 (0.4)	0	1.000
Total tumor size	2.0 (±0.6)	1.6 (±0.3)	<0.001
Invasive component size	1.5 (±0.3)	1.4 (±0.2)	0.104
Location, n (%)			0.142
Central	20 (8.5)	0
Peripheral	215 (91.5)	29 (100.0)
Histology, n (%)			0.024
Adenocarcinoma	206 (87.7)	20 (69.0)
Squamous cell carcinoma	18 (7.7)	6 (20.7)
Others	11 (4.7)	3 (10.3)
Number of dissected lymph nodes (±SD)	13.6 (±7.2)	2.1 (±4.2)	<0.001
Lymphovascular invasion, n (%)	73 (31.1)	7 (24.1)	0.444

SD, standard deviation; CEA, carcinoembryonic antigen; SUVmax, maximum standardized uptake value; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide; VATS, video-assisted thoracoscopic surgery.